Dissolvable heart stent could replace metal ones in major trial

NCT ID NCT07022587

Recruiting now Disease control Sponsor: Xijing Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a new dissolvable heart stent (Firesorb BRS) to a standard metal stent in 2000 people with coronary artery disease. The dissolvable stent is designed to support the artery temporarily and then disappear, potentially avoiding long-term risks of permanent stents. The main goal is to see if it works just as well at preventing heart-related events like heart attacks or repeat procedures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sirolimus
What this could lead to: If successful, this could offer a safer alternative to permanent metal stents, reducing long-term complications like late blood clots.
What could go wrong: This is a non-inferiority trial, meaning it aims to show the new scaffold is not worse than the current standard. Earlier dissolvable stents had higher clot risks, so caution is warranted.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder coronary stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE DE NOVO STENOSIS

Contacts and locations

Locations

Xijing Hospital
RECRUITING

Xi'an, Shannxi, 710032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.